Jazz Pharmaceuticals Reports Positive Trial Results


Jazz Pharmaceuticals Inc. (Nasdaq: JAZZ) announced upbeat results from a Phase III clinical trial of its fibromyalgia treatment sodium oxybate sending the stock price soaring $1.29 to $4.54.

About this Entry

This page contains a single entry by published on June 25, 2009 10:30 AM.

Analyst Widens Loss Outlook For Huntsman was the previous entry in this blog.

China Architectural Wins $500 Million Contract is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 5.12